Practitioner Review: Current best practice in the use of parent training and other behavioural interventions in the treatment of children and adolescents with attention deficit hyperactivity disorder

Grants

Funding Acknowledgements

David Daley: Fees from Eli Lilly, nonfinancial support from Eli Lilly, grants from Shire, personal fees from Shire, nonfinancial support from Shire, fees from Medice and nonfinancial support from Medice, outside the submitted work; and he has also received royalties from the sale of a self-help version of the New Forest Parenting Programme and research funding from NIHR. Saskia Van der Oord: Organisational financial interests: a paid consultant for designing a RCT of Plan-It Commander (Janssen Pharmaceuticals) and has received speaker's fees from MEDICE and Shire (all related to talks on nonpharmacological interventions). Research grants: ZonMW (Dutch Mental Health Research Funding Organization)/FWO (Research grant from Flanders Scientific Research Organization)/KU Leuven research grant (University Research Grant). Nonfinancial: Saskia Van der Oord has been involved in the development, implementation and trailing of 'Braingame Brian', an executive functioning game training for children with ADHD, and Zelf Plannen (Plan my Life) and Zelf Oplossingen bedenken (solution-focused treatment), two cognitive behavioural planning interventions for adolescents with ADHD. She has no financial interests in either of these interventions. Sam Cortese: Reimbursement for travel and accommodation expenses from the Association for Child and Adolescent Central Health (ACAMH), a nonprofit organisation, in relation to lectures that he delivered for ACAMH. Marina Danckaerts: Paid member of advisory boards organised by Shire, paid speaker at conferences (not product related) by Shire, Novartis, Medice and paid for consultancy for Neurotech Solutions. Organisational financial interests: department received research grants from Shire and Janssen-Cilag. Nonfinancial interests member of the scientific committee of the Belgian ADHD Guidelines and co-authored on papers on ADHD. Manfred Dopfner: Received consulting income and research support from Lilly, Medice, Shire, Janssen Cilag, Novartis, and Vifor and research support from the German Research Foundation, German Ministry of Education and Research, and German Ministry of Health. He received income as Head of the School for Child and Adolescent Behavior Therapy at the University of Cologne and royalties from treatment manuals, books and psychological tests published by Guilford, Hogrefe, Enke, Beltz, and Huber. Barbara J Van den Hoofdakker: Research grants from ZonMw (The Netherlands Organisation for Health Research and Development); NWO (The Netherlands Organisation for Scientific Research); UMCG (University Medical Centre Groningen). Receives royalties as one of the editors of 'Sociaal Onhandig' (published by Van Gorcum), a Dutch book for parents of children with PDD-NOS or ADHD that is being used in parent training. Nonfinancial: developed and evaluates several Dutch parent training programmes, without financial interests; is and has been a member of Dutch ADHD guideline groups; is an advisor of the Dutch Knowledge Centre for Child and Adolescent Psychiatry. David Coghill: Grants and personal fees from Shire, personal fees from Eli Lilly, grants from Vifor, personal fees from Novartis, personal fees from Oxford University Press, these are outside the submitted work. Margaret Thompson: Research grants from NIHR, Solent NHS Trust, European Union (ADDUCE), an MHRN unrestricted research grant from Shire, consultancy fees from Shire, conference sponsorship from Eunethydis, is a codeveloper of the New Forest Parenting package (NFPP), and receives dividends from the sale of the NFPP selfhelp manual.Philip Asherson: Received honoraria for consultancy to Shire, Eli-Lilly and Novartis; educational/research awards from Shire, Lilly, Novartis, Vifor Pharma, GW Pharma and QbTech; speaker at sponsored events for Shire, Lilly and Novartis. Tobias Banaschewski has served in an advisory or consultancy role for Actelion, Hexal Pharma, Lilly, Medice, Novartis, Oxford outcomes, Otsuka, PCM scientific, Shire and Viforpharma. He received conference support or speaker's fee by Medice, Novartis and Shire. He is/has been involved in clinical trials conducted by Shire and Viforpharma. He received royalities from Hogrefe, Kohlhammer, CIP Medien, Oxford University Press. Daniel Brandeis has worked as an unpaid advisor for an EU-funded neurofeedback trial. Jan Buitelaar has been in the past 3 years a consultant to/member of advisory board of and/or speaker for Janssen Cilag BV, Eli Lilly, Lundbeck, Shire, Roche, Medice, Novartis and Servier. He has received research support from Roche and Vifor. Ralf W. Dittmann has received compensation for serving as consultant or speaker, or he or the institution he works for have received research support or royalties from the companies or organisations indicated: EU (FP7 Programme), US National Institute of Mental Health (NIMH), German Federal Ministry of Health/Regulatory Agency (BMG/BfArM), German Federal Ministry of Education and Research (BMBF), German Research Foundation (DFG), Volkswagen Foundation, Boehringer Ingelheim, Ferring, Janssen-Cilag, Lilly, Lundbeck, Otsuka, Shire, Sunovion/Takeda and Theravance. Dr. Dittmann owns Eli Lilly stock. Chris Hollis has been a Co-investigator on a research grant from Shire Pharmaceutics to the University of Nottingham to investigate driving behaviour in adults with ADHD (no drug involved). Martin Holtmann has served in an advisory or consultancy role for Lilly, Shire and Medice, and received conference attendance support or was paid for public speaking by Bristol-Myers Squibb, Lilly, Medice, Neuroconn, and Shire. Aribert Rothenberger is member of an advisory board and speakers' bureau of Lilly, Shire, Medice and Novartis. He got research and travel support and an educational grant from Shire and research support from the German Research Society. Paramala Santosh declares no conflicts of interest. Cesar Soutullo has received research funds for Caja Navarra Foundation, Eli Lilly, Lundbeck Shire and TEVA. He has served as Consultant I Advisory Board for Alicia Koplowitz Foundation, Editorial Medica Panamericana, Eli Lilly, lnstituto de Salud Carlos III (FIS), NeuroTech Solutions Ltd, Spanish Health Ministry Quality Plan (Clinical Practice Guidelines on TDAH and Clinical Practice Guidelines on Depression), Rubio and Shire. He has served in the Speaker's Bureau/has given talks on Continuous Medical Education (not about a product) for: Eli Lilly, Shire, Universidad Internacional Menendez Pelayo and Universidad Internacional de La Rioja (UNIR). He has received Royalties from DOYMA, Editorial Medica Panamericana, EUNSA, Mayo Ediciones. Hans Christoph Steinhausen has worked as an advisor and speaker for the following pharmaceutical companies: Janssen-Cilag, Eli Lilly, Novartis, Medice, Shire and UCB and has also received unrestricted grants for postgraduate training courses or conferences and research by Janssen-Cilag, Eli Lilly, Novartis, Medice and Swedish Orphan International. He receives book royalties from Cambridge University Press, Elsevier, Hogrefe, Huber, Klett and Kohlhammer Publishers.Argyris Stringaris receives grant or research support from the Guy's & St Thomas' Charity, University College London for a joint project with Johnson and Johnson, the Wellcome Trust and the National Institute for Health Research. He also receives royalties from Cambridge University Press for The Maudsley Reader in Phenomenological Psychiatry, and Oxford University Press for Disruptive Mood: Irritability in Children and Adolescents. Eric Taylor receives royalties from Blackwell Wiley, Oxford University press, MacKeith Press. Ian C K Wong has received grants from European Union FP7 programme, during the conduct of the study; grants from Shire, grants from JanssenCilag, grants from Eli-Lily, grants from Pfizer, outside the submitted work; he is a member of the National Institute for Health and Clinical Excellence (NICE) ADHD Guideline Group and acted as an advisor to Shire. Alessandro Zuddas has received honoraria for participating to Advisory board or Data Safety Monitory Boards from Eli Lilly, Otsuka, Lundbeck, Takeda and EduPharma. He has also received royalties from Oxford University Press and Giunti OS, and research grants from Lundbeck, Roche, Shire and Vifor. Edmund Sonuga-Barke: Speaker fees, consultancy, research funding and conference support from Shire Pharma. Speaker fees from American University of Beirut, Janssen-Cilag, consultancy from Neurotech solutions, Copenhagen University and Berhanderling, Skolerne, KU Leuven. Book royalties from OUP and Jessica Kingsley. Financial support received from Aarhus Univerisity and Ghent University for visiting Professorship. Grants awarded from MRC, ESRC, Wellcome Trust, Solent NHS Trust, European Union, Child Health Research Foundation New Zealand, NIHR, Nuffield Foundation, Fonds Wetenschappelijk Onderzoek-Vlaanderen (FWO), MQ - Transforming Mental Health. Editor-in-Chief JCPP supported by a buy-out of time to Kings College London and a personal Honorarium. The remaining authors have declared no other potential or competing conflict of interest. The authors thank the parent support groups and clinicians for their assistance in the process of generating questions of clinical concern for this practitioner review. They also thank Joanna Lockwood and Danielle Beaton for assistance in the preparation of this manuscript.